A Phase 2 interventional study of SEL and FIR in Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Completed at 101 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-12-03.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 2, and was the 13th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 395 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 161 across the 16 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are:
Key Inclusion Criteria:
Screening laboratory parameters, as determined by the central laboratory:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
Drug: SEL · Drug: Placebo to match FIR · Drug: Placebo to match CILO
Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
Drug: FIR · Drug: Placebo to match CILO · Drug: Placebo to match SEL
Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
Drug: CILO · Drug: Placebo to match FIR · Drug: Placebo to match SEL
Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
Drug: SEL · Drug: FIR · Drug: Placebo to match CILO
Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
Drug: SEL · Drug: CILO · Drug: Placebo to match FIR
Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
Drug: FIR · Drug: CILO · Drug: Placebo to match SEL
Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
Drug: Placebo to match FIR · Drug: Placebo to match CILO · Drug: Placebo to match SEL
18 mg tablet administered orally once daily without regard to food
20 mg tablet administered orally once daily without regard to food
Also known as: GS-0976
30 mg tablet administered orally once daily without regard to food
Also known as: GS-9674
Tablet administered orally once daily without regard to food
Tablet administered orally once daily without regard to food
Tablet administered orally once daily without regard to food
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Time frame: First dose date up to 48 weeks plus 30 days
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.
Time frame: First dose date up to 48 weeks plus 30 days
Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48
Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network classification (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. The 95% CI was based on the Clopper-Pearson method.
Time frame: Week 48
Participants were enrolled at study sites in United States, Australia, Canada, Hong King and New Zealand. The first participant was screened on 21 Mar 2018. The last study visit occurred on 19 Nov 2019.
| Milestone | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 39 | 40 | 41 | 80 | 78 | 78 | 39 |
| Completed | 3 | 33 | 34 | 71 | 66 | 69 | 38 |
| Not completed | 36 | 7 | 7 | 9 | 12 | 9 | 1 |
| Withdrew: Randomized but never treated | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Unknown reason | 33 | 1 | 1 | 1 | 2 | 2 | 0 |
| Withdrew: Withdrew consent | 1 | 3 | 1 | 4 | 4 | 4 | 1 |
| Withdrew: Adverse event | 1 | 2 | 1 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 1 | 3 | 0 | 0 |
| Withdrew: Investigator's discretion | 0 | 1 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Non compliance with study drug | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| percentage of participants | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 84.6 | 85.0 | 92.5 | 88.6 | 96.1 | 91.0 | 79.5 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.
| percentage of participants | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | 94.9 | 100.0 | 97.5 | 98.7 | 96.1 | 100.0 | 94.9 |
Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network classification (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. The 95% CI was based on the Clopper-Pearson method.
| percentage of participants | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48 | 28.6 (3.7 to 71.0) | 12.1 (3.4 to 28.2) | 11.8 (3.3 to 27.5) | 15.5 (8.0 to 26.0) | 19.1 (10.6 to 30.5) | 20.9 (11.9 to 32.6) | 10.5 (2.9 to 24.8) |
Collected over First dose date up to 48 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selonsertib | 0/39 (0%) | 7/39 (17.9%) | 30/39 (76.9%) |
| Firsocostat | 0/40 (0%) | 3/40 (7.5%) | 30/40 (75%) |
| Cilofexor | 0/40 (0%) | 8/40 (20%) | 34/40 (85%) |
| SEL + FIR | 0/79 (0%) | 7/79 (8.9%) | 67/79 (84.8%) |
| SEL + CILO | 1/77 (1.3%) | 10/77 (13%) | 68/77 (88.3%) |
| FIR + CILO | 0/78 (0%) | 8/78 (10.3%) | 66/78 (84.6%) |
| Placebo | 0/39 (0%) | 2/39 (5.1%) | 29/39 (74.4%) |
| Event | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo |
|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/39 | 0/40 | 3/40 | 1/79 | 0/77 | 0/78 | 0/39 |
| Abdominal painGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 0/39 |
| Abdominal pain lowerGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 0/39 |
| ConstipationGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 0/39 |
| DysphagiaGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 0/39 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 1/39 |
| Umbilical herniaGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 0/39 |
| Colonic abscessInfections and infestations | 1/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 0/39 |
| Kidney infectionInfections and infestations | 0/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 1/39 |
| Meniscus injuryInjury, poisoning and procedural complications | 1/39 | 0/40 | 0/40 | 0/79 | 0/77 | 0/78 | 0/39 |
| Event | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo |
|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 7/39 | 5/40 | 8/40 | 12/79 | 20/77 | 19/78 | 5/39 |
| NauseaGastrointestinal disorders | 3/39 | 6/40 | 3/40 | 20/79 | 10/77 | 10/78 | 1/39 |
| Upper respiratory tract infectionInfections and infestations | 4/39 | 7/40 | 4/40 | 14/79 | 12/77 | 8/78 | 9/39 |
| HeadacheNervous system disorders | 4/39 | 7/40 | 4/40 | 11/79 | 6/77 | 15/78 | 3/39 |
| Abdominal painGastrointestinal disorders | 7/39 | 2/40 | 3/40 | 6/79 | 6/77 | 7/78 | 2/39 |
| FatigueGeneral disorders | 5/39 | 7/40 | 3/40 | 14/79 | 9/77 | 8/78 | 3/39 |
| DiarrhoeaGastrointestinal disorders | 2/39 | 5/40 | 0/40 | 11/79 | 7/77 | 13/78 | 2/39 |
| Urinary tract infectionInfections and infestations | 6/39 | 3/40 | 5/40 | 9/79 | 9/77 | 6/78 | 2/39 |
| NasopharyngitisInfections and infestations | 2/39 | 4/40 | 6/40 | 3/79 | 3/77 | 9/78 | 5/39 |
| ConstipationGastrointestinal disorders | 2/39 | 0/40 | 4/40 | 8/79 | 11/77 | 6/78 | 3/39 |
The Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 59 ± 10.4 | 60 ± 10.0 | 57 ± 10.2 | 59 ± 8.3 | 60 ± 9.0 | 61 ± 8.4 | 61 ± 8.2 | 60 ± 9.0 |
| Sex: Female, Male(Participants) | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 24 | 25 | 29 | 49 | 51 | 48 | 27 | 253 |
| Male | 15 | 15 | 11 | 30 | 26 | 30 | 12 | 139 |
| Race/Ethnicity, Customized(Participants) | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 4 |
| Race — Asian | 7 | 3 | 0 | 3 | 4 | 5 | 3 | 25 |
| Race — Black | 0 | 1 | 0 | 1 | 2 | 2 | 1 | 7 |
| Race — Native Hawaiian or Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — White | 30 | 35 | 40 | 73 | 68 | 68 | 35 | 349 |
| Race — Not Permitted | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — Other | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 5 |
| Race/Ethnicity, Customized(Participants) | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Ethinicity — Hispanic or Latino | 8 | 9 | 14 | 18 | 25 | 17 | 14 | 105 |
| Ethinicity — Not Hispanic or Latino | 31 | 31 | 26 | 60 | 52 | 60 | 25 | 285 |
| Ethinicity — Not Permitted | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Region of Enrollment(participants) | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| New Zealand | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Canada | 3 | 2 | 2 | 5 | 4 | 3 | 3 | 22 |
| Hong Kong | 2 | 0 | 0 | 3 | 2 | 2 | 1 | 10 |
| United States | 30 | 35 | 37 | 67 | 66 | 66 | 35 | 336 |
| Australia | 3 | 3 | 1 | 4 | 5 | 7 | 0 | 23 |
| Diabetes Mellitus Status(Participants) | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Present | 26 | 30 | 27 | 57 | 58 | 57 | 27 | 282 |
| Absent | 13 | 10 | 13 | 22 | 19 | 21 | 12 | 110 |
| Cirrhosis Status(Participants) | Selonsertib | Firsocostat | Cilofexor | SEL + FIR | SEL + CILO | FIR + CILO | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Cirrhotic | 21 | 22 | 22 | 46 | 46 | 42 | 22 | 221 |
| Non-Cirrhotic | 18 | 18 | 18 | 33 | 31 | 36 | 17 | 171 |
Showing the first 100 of 101 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Oct 2019, 19 months.
Results were first posted in Dec 2020, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 19 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Selonsertib · Firsocostat · Cilofexor
Non-alcoholic Fatty Liver Disease →